Department of Radiation Oncology, Saad Specialist Hospital, P,O, Box 30353, Al Khobar 31952, Saudi Arabia.
Radiat Oncol. 2013 Sep 5;8:207. doi: 10.1186/1748-717X-8-207.
The goal of this study was to assess a possible dosimetric advantage of intensity modulated radiotherapy (IMRT) of upper abdominal malignancies compared to three-dimensional conformal radiotherapy (3DCRT), and to assess the impact of IMRT on acute toxicity.
Thirty-one unselected consecutive patients with upper abdominal malignancies were treated with definitive (n =16) or postoperative (n =15) IMRT. Twenty-one patients (67.7%) received concomitant chemotherapy. 3DCRT plans were generated for comparison, and analysis of variance (ANOVA) for repeated measurements was used to test for significant difference of dosimetric parameters. Acute toxicity was assessed weekly using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale.
IMRT plans showed a small but statistically significant improvement of the conformity index compared to 3DCRT plans (difference (95% confidence interval), -0.06 (-0.109 to-0.005); p = 0.03). The homogeneity index was not significantly improved (p = 0.10). A significantly reduced high dose volume on cost of a significantly increased low dose volume was observed for the kidneys. The acute toxicity appeared to be less than commonly reported for corresponding patients treated with 3DCRT. No patient developed grade 3 or 4 non-hematological acute toxicity, and the most common grade 2 toxicity was vomiting (9.7%).
IMRT offers the potential of a clinically relevant dosimetric advantage compared to 3DCRT in terms of a reduced acute toxicity. Further optimization of the radiotherapy technique and more clinical trials are required before IMRT is routinely used for upper abdominal malignancies.
本研究旨在评估与三维适形放疗(3DCRT)相比,调强放疗(IMRT)在上腹部恶性肿瘤中的可能剂量优势,并评估 IMRT 对急性毒性的影响。
31 例未经选择的上腹部恶性肿瘤患者接受了根治性(n=16)或术后(n=15)IMRT 治疗。21 例患者(67.7%)接受了同期化疗。生成了 3DCRT 计划进行比较,并使用重复测量方差分析(ANOVA)来测试剂量学参数的显著差异。使用常见不良事件术语标准(CTCAE)分级量表每周评估急性毒性。
与 3DCRT 计划相比,IMRT 计划显示出一致性指数的微小但具有统计学意义的改善(差异(95%置信区间),-0.06(-0.109 至-0.005);p=0.03)。均匀性指数没有显著改善(p=0.10)。观察到肾脏的高剂量体积显著减少,低剂量体积显著增加。急性毒性似乎低于用 3DCRT 治疗的相应患者的常见报告。没有患者发生 3 级或 4 级非血液学急性毒性,最常见的 2 级毒性是呕吐(9.7%)。
与 3DCRT 相比,IMRT 在上腹部恶性肿瘤中具有降低急性毒性的潜在临床相关剂量优势。在常规使用 IMRT 治疗上腹部恶性肿瘤之前,需要进一步优化放疗技术并进行更多临床试验。